Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive|HER2 Positive Breast Carcinoma|HER2/Neu Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Fulvestrant|OTHER: Laboratory Biomarker Analysis|DRUG: Lapatinib Ditosylate|OTHER: Placebo Administration
Sponsor: National Cancer Institute (NCI)